Fårö Capital divests further EQL shares to enable increased institutional ownership and create more liquidity in the share

As EQL grows larger, and ahead of a future NASDAQ listing, it is desirable to broaden the ownership base and enable more institutions to become owners of EQL. In the long term, this contributes to more liquid trading in the share and a wider interest in the company.

Fårö has today sold 1 million shares to an institutional buyer base and after the sale owns 7,427 million shares corresponding to 25,5 % of the shares and capital.

For more information contact:

Axel Schörling,

CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has more than 25 niche generics (i.e., generics with limited competition apart from the original drug) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2023 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets. EQL Pharma AB has its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.